pregnancy or lactation presence of medical contraindications for inclusion in the examination in the opinion of the attending physician, in particular: a) comorbidities: i) clinically significant hepatic or renal insufficiency; ii) epilepsy or seizures (current or history of); iii) psychiatric or somatic diseases (present or in a history of agitation or confusion, delirium syndromes or exogenous psychoses); iv) cardiovascular diseases such as: severe congestive heart failure, cardiomyopathy, myocarditis, grade ii-iv av block, bradycardia, qt prolongation, perceived u waves or family history of congenital long qt syndrome, severe ventricular arrhythmias a history of heart (including torsade de pointes); v) diseases or conditions that significantly reduce the immunity of a patient (e.g. solid organ transplant, bone marrow transplantation (bmt), aids, immune biologics and / or high-dose steroids (> 20 mg prednisone daily). b) hypersensitivity to any component of the preparation, c) parallel use of drugs that prolong the qt interval, d) hypokalemia or hypomagnesaemia, e) untreated angle-closure glaucoma, f) use of amantadine currently or in the last 3 months prior to study inclusion; g) participation in another clinical program

pregnancy or lactation presence of medical contraindications for inclusion in the examination in the opinion of the attending physician, in particular: a) comorbidities: i) clinically significant hepatic or renal insufficiency; ii) epilepsy or seizures (current or history of); iii) psychiatric or somatic diseases (present or in a history of agitation or confusion, delirium syndromes or exogenous psychoses); iv) cardiovascular diseases such as: severe congestive heart failure, cardiomyopathy, myocarditis, grade ii-iv av block, bradycardia, qt prolongation, perceived u waves or family history of congenital long qt syndrome, severe ventricular arrhythmias a history of heart (including torsade de pointes); v) diseases or conditions that significantly reduce the immunity of a patient (e.g. solid organ transplant, bone marrow transplantation (bmt), aids, immune biologics and / or high-dose steroids (> 20 mg prednisone daily). b) hypersensitivity to any component of the preparation, c) parallel use of drugs that prolong the qt interval, d) hypokalemia or hypomagnesaemia, e) untreated angle-closure glaucoma, f) use of amantadine currently or in the last 3 months prior to study inclusion; g) participation in another clinical program

1. pregnancy or lactation 2. presence of medical contraindications for inclusion in the examination in the opinion of the attending physician, in particular: a) comorbidities: i) clinically significant hepatic or renal insufficiency; ii) epilepsy or seizures (current or history of); iii) psychiatric or somatic diseases (present or in a history of agitation or confusion, delirium syndromes or exogenous psychoses); iv) cardiovascular diseases such as: severe congestive heart failure, cardiomyopathy, myocarditis, grade ii-iv av block, bradycardia, qt prolongation, perceived u waves or family history of congenital long qt syndrome, severe ventricular arrhythmias a history of heart (including torsade de pointes); v) diseases or conditions that significantly reduce the immunity of a patient (e.g. solid organ transplant, bone marrow transplantation (bmt), aids, immune biologics and / or high-dose steroids (> 20 mg prednisone daily). b) hypersensitivity to any component of the preparation, c) parallel use of drugs that prolong the qt interval, d) hypokalemia or hypomagnesaemia, e) untreated angle-closure glaucoma, f) use of amantadine currently or in the last 3 months prior to study inclusion; g) participation in another clinical program

1. pregnancy or lactation 2. presence of medical contraindications for inclusion in the examination in the opinion of the attending physician, in particular: a) comorbidities: i) clinically significant hepatic or renal insufficiency; ii) epilepsy or seizures (current or history of); iii) psychiatric or somatic diseases (present or in a history of agitation or confusion, delirium syndromes or exogenous psychoses); iv) cardiovascular diseases such as: severe congestive heart failure, cardiomyopathy, myocarditis, grade ii-iv av block, bradycardia, qt prolongation, perceived u waves or family history of congenital long qt syndrome, severe ventricular arrhythmias a history of heart (including torsade de pointes); v) diseases or conditions that significantly reduce the immunity of a patient (e.g. solid organ transplant, bone marrow transplantation (bmt), aids, immune biologics and / or high-dose steroids (> 20 mg prednisone daily). b) hypersensitivity to any component of the preparation, c) parallel use of drugs that prolong the qt interval, d) hypokalemia or hypomagnesaemia, e) untreated angle-closure glaucoma, f) use of amantadine currently or in the last 3 months prior to study inclusion; g) participation in another clinical program